Anavex Life Sciences Corp. (NASDAQ: AVXL) Securities Class Action

USDC – Southern District of New York

10/6/2026

CLASS PERIOD: november 26, 2025 – august 28, 2026
LEAD PLAINTIFF DEADLINE: november 30, 2026

Please complete the form below to contact Kaplan Fox regarding the Anavex Life Sciences class action:

Principal Contacts

About the Anavex Life Sciences class action lawsuit

A securities class action has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors who purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026 (the “Class Period”). The case was filed in the U.S. District Court for the Southern District of New York.

Investors who want to ask the court to appoint them lead plaintiff must do so by November 30, 2026. If you invested in Anavex during the Class Period and lost money, contact Kaplan Fox using the form on this page, by emailing pmayer@kaplanfox.com, or by calling (646) 315-9003.

What the lawsuit alleges

The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that Anavex lacked adequate internal controls and that Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling.

What happened to Anavex Life Sciences stock

On May 11, 2026, according to the complaint, the Company filed a notification of late filing with the SEC and disclosed that it had “terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy.” On this news, Anavex stock fell $0.18 per share, or 5.55%, to close at $3.06 on May 12, 2026.

Then, on August 28, 2026, according to the complaint, Anavex filed an Amended 2025 Annual Report with the SEC. The report stated, in part, that as a result of a review by the Special Committee, management, in consultation with the Audit Committee of the Board, “concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025” and that “the Company’s disclosure controls and procedures were not effective.” On this news, Anavex stock fell $0.19 per share, or 6.35%, to close at $2.80 on August 31, 2026, thereby injuring investors further.

Who may be eligible

The proposed class includes investors who purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026. If you bought during that period and lost money, you may be a member of the class.

Lead plaintiff deadline: November 30, 2026

A lead plaintiff is an investor the court appoints to represent the class and oversee the case on its behalf. Class members who want to serve in that role must move the court no later than November 30, 2026. You need not seek to become a lead plaintiff in order to share in any possible recovery. If you have losses, contact us to learn more about the lead plaintiff process.

Case updates

• November 30, 2026: Deadline to ask the court to be appointed lead plaintiff.

Frequently asked questions

Do I have to become lead plaintiff to recover?

No. You need not seek to become a lead plaintiff in order to share in any possible recovery.

What if I bought Anavex outside the Class Period?

The complaint as filed covers purchases between November 26, 2025 and August 28, 2026. Contact us if you are not sure whether your purchases qualify.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com